Introducing Joint Network
Posted on: 26-02-2025
Introducing our MSK Innovation Network
Our approach to innovation
Innovation
We are the first MSK charity to actively support start-ups and entrepreneurs.
Our approach to innovation follows in the footsteps of our founder, Ronald Furlong, who combined a highly successful career as an orthopaedic surgeon with an equally successful career as an entrepreneur.
We support entrepreneurially-minded Early Career Researchers who have successfully completed their research projects within MSK health, or who are working on technologies with a potential application to MSK health. We provide them with funding, education, mentoring and networking support to accelerate the translation of their research ideas into new products or services.
Our Ronald Furlong Fund supports the development of innovative and commercially viable ideas from UK start-ups.
Our innovation partners
We work with partners to accelerate the translation of research ideas into new products or services.
Innovation stories
Innovation
Innovation
AI in MSK Education Series: Ensuring data quality in AI: Practical and ethical challenges
Posted on: 12-02-2025
This webinar features experts in data quality and related ethical challenges. The talks focus on addressing common challenges associated with the use of AI in clinical research including data bias, missing data, and ethical concerns.
Innovation
Using the ‘Walled Garden’ approach to MSK Innovation
Posted on: 30-12-2024
Working with the Impeller Ventures’ Walled Garden allows us to take a more proactive approach to musculoskeletal (MSK) innovation.
Investing in start ups
Through our Ronald Furlong Fund we invest in entrepreneurial people and organisations delivering breakthrough MSK health innovations.
We have investments in a growing number of early stage companies pioneering breakthrough MSK technologies.
Deploys state-of-the-art AI and biomechanical modelling to help clinicians design better fitting prosthetic sockets.
Pioneering use of a nanoclay in injectable gel form that can carry biologic drugs capable of augmenting bone tissue regeneration.
Commercialising world’s first patented bio-specific solution for the targeted diagnosis and treatment of bone microfractures.